NCT04786223View on ClinicalTrials.gov

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

C-11 ER-176

Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.

DIAGNOSTIC_TEST

Blood Test

Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Val Lowe

OTHER